Health Care M&A Deals, March 5, 2021

The Health Care M&A deals chart is a selection of transactions announced during the prior week(s). The M&A transactions presented here are from our HealthCareMandA.com Deal Database, which is updated daily to provide our subscribers with the most up-to-date information and trends in the healthcare industry.

The largest deal of the week by disclosed price is Amgen’s acquisition of Five Prime Therapeutics for $1.9 billion. Five Prime Therapeutics Five Prime Therapeutics is a clinical-stage biotechnology company focused on developing immuno-oncology and targeted cancer therapies. The company collaborates with leading global pharmaceutical companies and has therapies in pre-clinical and clinical development. The acquisition includes Bemarituzumab, a phase 3 ready, first-in-class program for gastric cancer, the third leading cause of cancer mortality worldwide. Amgen will leverage its presence in Japan and other Asia-Pacific markets to maximize bemarituzumab’s potential. The deal is expected to close Q2:21.

To subscribe to our Health Care M&A deals chart and more, visit our membership site. HealthCareMandA.com is devoted to healthcare merger and acquisition data for the serious analyst and investor. Every day, this service alerts you to developments in all the key segments of the health care service and technology markets.